Amgen (AMGN) Intangibles (2009 - 2026)
Amgen (AMGN) recorded quarterly Intangibles of $21.4 billion in Q1 2026, down 4.03% quarter-over-quarter from $22.3 billion in Q4 2025, and up 345.4% on a YoY basis from $4.8 billion in Q1 2025.
Amgen (AMGN) Intangibles (2009 - 2026) Analysis & Trends
Amgen's Intangibles history runs 18 years deep, the most recent figure standing at $21.4 billion for Q1 2026.
- In Q1 2026, Intangibles rose 345.4% year-over-year to $21.4 billion; the TTM figure through Mar 2026 stood at $21.4 billion (up 345.4% YoY), while the FY2025 annual figure was $22.3 billion, down 19.58% from the prior year.
- Intangibles was $21.4 billion for Q1 2026 at Amgen, down from $22.3 billion in the prior quarter.
- In the past five years, Intangibles ranged from a high of $32.6 billion in Q4 2023 to a low of $350.0 million in Q2 2025.
- Historically, Intangibles has averaged $19.0 billion across 5 years, with a median of $16.1 billion in 2022.
- The sharpest annual moves came in 2025 and 2026: Intangibles sank 98.84% in 2025, then soared 345.4% in 2026.
- A 5-year view of Intangibles shows it stood at $16.1 billion in 2022, then surged by 102.99% to $32.6 billion in 2023, then declined by 15.14% to $27.7 billion in 2024, then dropped by 19.58% to $22.3 billion in 2025, then retreated by 4.03% to $21.4 billion in 2026.
- The last three Intangibles figures came in at $21.4 billion (Q1 2026), $22.3 billion (Q4 2025), and $23.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 24.45 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.37 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 49.06 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 50.87 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 18.24 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | 10.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.38 Bn |
| Dec 31, 2025 | 22.28 Bn |
| Sep 30, 2025 | 23.14 Bn |
| Jun 30, 2025 | 350.00 Mn |
| Mar 31, 2025 | 4.80 Bn |
| Dec 31, 2024 | 27.70 Bn |
| Sep 30, 2024 | 28.92 Bn |
| Jun 30, 2024 | 30.17 Bn |
| Mar 31, 2024 | 31.37 Bn |
| Dec 31, 2023 | 32.64 Bn |
| Sep 30, 2023 | 13.15 Bn |
| Jun 30, 2023 | 14.63 Bn |
| Mar 31, 2023 | 15.39 Bn |
| Dec 31, 2022 | 16.08 Bn |
| Sep 30, 2022 | 13.27 Bn |
| Jun 30, 2022 | 13.93 Bn |
| Mar 31, 2022 | 14.57 Bn |
| Dec 31, 2021 | 15.18 Bn |
| Sep 30, 2021 | 14.66 Bn |
| Jun 30, 2021 | 15.31 Bn |